HC Wainwright Analysts Reduce Earnings Estimates for RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Stock analysts at HC Wainwright decreased their Q2 2026 EPS estimates for Ultragenyx Pharmaceutical in a report released on Monday, May 11th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of ($1.21) for the quarter, down from their previous forecast of ($1.20). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($4.61) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($4.27) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The company had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. During the same quarter in the previous year, the firm posted ($1.57) earnings per share. The business’s revenue for the quarter was down 2.2% compared to the same quarter last year.

Other equities analysts also recently issued research reports about the company. Wall Street Zen downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday. Barclays dropped their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th. Wedbush decreased their price target on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. JPMorgan Chase & Co. lowered their price target on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research report on Thursday, March 12th. Finally, Truist Financial raised shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $60.41.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE opened at $26.84 on Wednesday. Ultragenyx Pharmaceutical has a 52-week low of $18.29 and a 52-week high of $42.37. The firm has a market capitalization of $2.64 billion, a P/E ratio of -4.39 and a beta of 0.39. The stock has a 50 day moving average price of $22.88 and a 200-day moving average price of $26.64.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, EVP Erik Harris sold 10,539 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $240,289.20. Following the sale, the executive vice president owned 89,515 shares of the company’s stock, valued at $2,040,942. This trade represents a 10.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.70, for a total transaction of $190,884.30. Following the completion of the sale, the chief financial officer owned 86,669 shares of the company’s stock, valued at $1,967,386.30. This represents a 8.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 111,522 shares of company stock worth $2,543,214. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. lifted its holdings in shares of Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after buying an additional 2,057,951 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 614.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock worth $65,205,000 after acquiring an additional 1,864,164 shares during the period. Norges Bank purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at $29,004,000. Millennium Management LLC increased its position in Ultragenyx Pharmaceutical by 787.6% during the fourth quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company’s stock valued at $20,255,000 after acquiring an additional 781,431 shares during the last quarter. Finally, Vestal Point Capital LP bought a new position in Ultragenyx Pharmaceutical in the third quarter valued at about $22,560,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.